Latest Headlines

  1. CDMO GBI Biomanufacturing Announces New President 1/6/2026

    GBI Biomanufacturing, a U.S.-based biopharmaceutical CDMO providing integrated development and cGMP manufacturing services for complex biologics, today announced that Jesse McCool, Ph.D. has been appointed President.

  2. Symbiosis Initiates Commercial Drug Manufacturing At New FDA-Inspected Production Facility 1/6/2026

    (Symbiosis), a leading sterile fill finish contract manufacturing organisation (CMO), has manufactured their first 10,000 vial batch at the company’s new facility in Stirling, UK.

  3. Samsung Biologics Expands U.S. Manufacturing Capabilities With Strategic Acquisition Of Human Genome Sciences From GSK 12/22/2025

    This strategic move secures Samsung Biologics’ first U.S.-based manufacturing site, a significant expansion of the company’s global footprint and its long-term commitment to the U.S. market.

  4. Techceuticals Releases 2026 Schedule For In-Person Solid Dosage Manufacturing Training 12/19/2025

    Techceuticals has announced its 2026 training schedule for solid dosage manufacturing, featuring a full lineup of two-day, hands-on courses covering tablet making, encapsulation, granulation, film coating, and end-to-end solid dosage processes.

  5. Sanofi Toronto Equipment Assets Auction Announced For January 2026 12/19/2025

    Federal Equipment Company, a trusted global provider of surplus pharmaceutical and chemical processing equipment, announced it will conduct a two-day online auction on behalf of Sanofi featuring quality process and laboratory equipment surplus to the company’s ongoing operational needs.

  6. Alnylam Announces $250M Investment To Expand U.S. Manufacturing Capacity In Massachusetts For RNAi Therapeutics 12/18/2025

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing to invest $250 million to advance what is poised to become the industry’s first fully dedicated, proprietary, siRNA enzymatic-ligation manufacturing facility. This investment is expected to meaningfully expand capacity, significantly reduce production costs, and position Alnylam to support future launches across its growing pipeline of potential new medicines.

  7. Driving Pharma 4.0: Flexible & Sustainable Facilities At PHARMAP 2026 12/18/2025

    The shift towards Pharma 4.0 is revolutionising pharmaceutical manufacturing, introducing highly advanced, digitally interconnected and automated production plants that simplify processes and transform the industry. The future of pharmaceutical facilities is going to be the central theme of discussions at PHARMAP 2026 in Amsterdam on 20-21 April.

  8. CDMO Halo Pharma Adds New Gerteis Roller Compactor 12/18/2025

    Halo Pharma, a leading CDMO specializing in pharmaceutical development and manufacturing services, is expanding its manufacturing capabilities at its Whippany, New Jersey facility with the addition of a Gerteis Macro-Pactor®, a versatile roller compactor that enhances the company’s ability to manage complex formulations, improve process efficiency, and deliver consistent solid-dose pharmaceutical products.

  9. Groninger Apprentices Mark Career Milestones 12/17/2025

    groninger USA proudly announces the graduation of apprentices Connor Benito and Logan Busteed, who today receive their Associate Degrees in Mechatronics Engineering Technology from Central Piedmont Community College. Both young professionals joined groninger’s highly regarded apprenticeship path and now mark a milestone in their technical careers.

  10. CDMO Incog Biopharma Announces $200 Million Manufacturing Expansion In Indiana 12/17/2025

    INCOG BioPharma Services, a leading contract development and manufacturing organization (CDMO), today announced another major expansion with an investment of approximately $200 million in its manufacturing facility in Fishers, Indiana. This investment will significantly increase the company’s injectable drug product manufacturing capacity.